Alpha 2.0
Login Register
» Articles » PMID: 38093160

Zilucoplan: First Approval

Overview
Journal Drugs
Specialty Pharmacology
Date 2023 Dec 13
PMID 38093160
Authors
Matt Shirley
Affiliations
Soon will be listed here.
Abstract

Zilucoplan (Zilbrysq) is a subcutaneously administered macrocyclic peptide inhibitor of complement component 5 (C5 inhibitor) being developed by UCB for the treatment of generalised myasthenia gravis (gMG). Zilucoplan received its first approval, in Japan, in September 2023 for the treatment of gMG in adult patients who inadequately respond to steroids or other immunosuppressants and are positive for anti-acetylcholine receptor (AChR) antibodies. Subsequently, zilucoplan was approved in the USA in October 2023 for the treatment of gMG in adult patients who are anti-AChR antibody positive and in the EU in December 2023 as an add-on to standard therapy for the treatment of gMG in adult patients who are anti-AChR antibody positive. Zilucoplan is also currently under regulatory review in Australia and Canada for use in the treatment of gMG. This article summarises the milestones in the development of zilucoplan leading to this first approval for gMG.

Citing Articles

Myasthenia gravis in 2025: five new things and four hopes for the future.

Binks S, Morse I, Ashraghi M, Vincent A, Waters P, Leite M J Neurol. 2025; 272(3):226.

PMID: 39987373 PMC: 11846739. DOI: 10.1007/s00415-025-12922-7.

New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making.

Gerischer L, Doksani P, Hoffmann S, Meisel A BioDrugs. 2025; 39(2):185-213.

PMID: 39869260 PMC: 11906560. DOI: 10.1007/s40259-024-00701-1.

cyclicpeptide: a Python package for cyclic peptide drug design.

Yang L, Cao S, Liu L, Zhu R, Wu D Brief Bioinform. 2025; 26(1.

PMID: 39783893 PMC: 11713021. DOI: 10.1093/bib/bbae714.

Efgartigimod: A Review in Generalised Myasthenia Gravis.

Blair H Drugs. 2024; 84(11):1463-1474.

PMID: 39511131 DOI: 10.1007/s40265-024-02101-9.

Complement-targeted therapeutics: Are we there yet, or just getting started?.

Ricklin D Eur J Immunol. 2024; 54(12):e2350816.

PMID: 39263829 PMC: 11628912. DOI: 10.1002/eji.202350816.

References
1.
Howard Jr J, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y . Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023; 22(5):395-406. DOI: 10.1016/S1474-4422(23)00080-7. View
2.
Mammen A, Amato A, Dimachkie M, Chinoy H, Hussain Y, Lilleker J . Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial. Lancet Rheumatol. 2023; 5(2):e67-e76. PMC: 10009502. DOI: 10.1016/s2665-9913(23)00003-6. View
3.
De Leeuw E, Van Damme K, Declercq J, Bosteels C, Maes B, Tavernier S . Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial. Respir Res. 2022; 23(1):202. PMC: 9361275. DOI: 10.1186/s12931-022-02126-2. View
4.
Wilkinson T, Dixon R, Page C, Carroll M, Griffiths G, Ho L . ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a.... Trials. 2020; 21(1):691. PMC: 7393340. DOI: 10.1186/s13063-020-04584-9. View
5.
Tang G, Tang Y, Dhamnaskar K, Hoarty M, Vyasamneni R, Vadysirisack D . Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation. Front Immunol. 2023; 14:1213920. PMC: 10446491. DOI: 10.3389/fimmu.2023.1213920. View